STAT+: Recursion, the AI drug development company, cuts more jobs after finalizing Exscientia merger

Recursion Pharmaceuticals, one of the most advanced companies using artificial intelligence and machine learning tools to expedite drug development, laid off employees after closing a merger last week.

Continue to STAT+ to read the full story…

Cardiovascular risks of COVID-19 antivirals

Study reviews cardiovascular side effects linked to antiviral therapies for COVID-19, highlighting the need for careful consideration when prescribing these drugs to high-risk patients.

September 16, 2024

Organigram Sells Units to Raise C$25 MIllion

Organigram Announces Pricing of Overnight Marketed Public Offering TORONTO–(BUSINESS WIRE), March 27, 2024–Organigram Holdings Inc. (“Organigram” or the “Company”) (TSX: OGI; NASDAQ: OGI), announces today

March 27, 2024

Doctors need to pay more attention to non-physical side effects of health care

When faced with a new diagnosis, a patient knows that the necessary treatment may make her feel lousy. What she doesn’t always account for, though,

August 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.